Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-15
2010-10-05
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S472000
Reexamination Certificate
active
07807706
ABSTRACT:
Compounds of formula I:wherein R1, R2, R3, R4, R5, R6, R7, R8, R9and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
REFERENCES:
patent: 3579524 (1971-05-01), Van Dyke et al.
patent: 3993617 (1976-11-01), Schwan
patent: 5175157 (1992-12-01), Psiorz et al.
patent: 5681954 (1997-10-01), Yamamoto et al.
patent: 2003/0212094 (2003-11-01), Yamabe et al.
patent: 2005/0026976 (2005-02-01), Curtin et al.
patent: 2007/0082907 (2007-04-01), Canada et al.
patent: 620 654 (1963-01-01), None
patent: 0 548 934 (1993-06-01), None
patent: WO-99/26927 (1999-06-01), None
patent: WO-2004/024702 (2004-03-01), None
patent: WO-2004/031178 (2004-04-01), None
patent: WO-2005/040157 (2005-05-01), None
patent: WO-2005/074643 (2005-08-01), None
patent: WO-2005/085214 (2005-09-01), None
patent: WO-2005/085216 (2005-09-01), None
patent: WO-2006/020879 (2006-02-01), None
patent: WO-2006/047237 (2006-05-01), None
patent: WO-2006/091496 (2006-08-01), None
Mertz et al., Synthetic Receptors for CG Base Pairs, 2000, Organic Letters, vol. 2, No. 19, 2931-2934.
Vippagunta et al., Crystalline solids, 2001, Advanced Drug Delivery Reviews, 48, pp. 3 and 18.
Barr et al.; Journal of Organometallic Chemistry, vol. 302, No. 1, Mar. 11, 1986, pp. 117-126, XP002383544.
Hoarau C et al: Synthesis, No. 5, 2000, pp. 655-660, XP002383545.
Rys V et al: European Journal of Organic Chemistry, No. 7, Apr. 2003, pp. 1231-1237, XP002383546.
Clayden J et al: Organic Letters, vol. 2, No. 26, 2000, pp. 4229-4232, XP002345295.
Couture A et al: Tetrahedron Letters, vol. 43, No. 12, Mar. 18, 2002, pp. 2207-2210 XP004344002.
Casagrande C et al: IL Farmaco, Edizione Scientifica, vol. 27, No. 6, Jun. 1972, pp. 445-470, XP000 571647.
Bonnefous at al., Bioorganic & Medicinal Chemistry Letters, vol. 15, p. 4354-4358 (2005).
Bonnefous et al. (Merck), poster presented at the 229th National Meeting of the American Chemical Society, San Diego, CA, Mar. 2005; poster, MEDI-37.
Yamamoto Y. et al: Organic and Biomoleculae chemistry, vol. 2, No. 9, May 2004, pp. 1287-1294, XP002357868.
Moreau a at al: Tetrahedron, vol. 60, No. 29, Jul. 12, 2004, pp. 6169-6176 XP002357869.
Hatt H H et al: Journal of the Chemical Society, 1952, pp. 199-205 XP002357871.
Bohme H et al: Die Pharmazie, No. 25, 1970, pp. 283-289, XP002357872.
Bailey DM et al: Journal of Medicinal Chemistry, vol. 14, No. 3, pp. 240-241, XP002357873, 1971.
Mori M et al: Journal of Organic Chemistry, vol. 43, No. 9, Apr. 28, 1978, pp. 1864-1867, XP002357874.
Grigg R et al: Tetrahedron Letters, vol. 44, No. 37, Sep. 8, 2003, pp. 6979-6982, XP004447066.
Norman M H et al.: Journal of Medicinal Chemistry, vol. 39, No. 1, 1996, pp. 149-157, XP000982309.
Zhuang Z-P et al: Journal of Medicinal Chemistry, vol. 41, No. 2, Jan. 15, 1998, pp. 157-166, XP002357875.
Norman M H, et al: Journal of Medicinal Chemistry, vol. 36, No. 22, Oct. 29, 1993, pp. 3417-3423, XP002357876.
Ahn K H et al: Bioorganic & Medicinal Chemistry Letters, vol. 9, No. 10, May 17, 1999, pp. 1379-1384, XP004164896.
Sugimoto H et al: Journal of Medicinal Chemistry, vol. 35, No. 24, 1992, pp. 4542-4548, XP002319779.
Mayer P et al: Journal of Medicinal Chemistry, vol. 43, Sep. 19, 2000, pp. 3653-3664, XP001183987.
Breytenbach J C et al: Bioorganic & Medicinal Chemistry Letters, vol. 10, No. 15, Aug. 7, 2000, pp. 1629-1631, XP004213210.
Anderson P S et al: Journal of Organic Chemistry, vol. 44, No. 9, 1979, pp. 1519-15, XP002981802.
Luzzio F A et al: Tetrahedron Letters, vol. 40, No. 11, Mar. 12, 1999, pp. 2087-2090, XP002357870.
Clayton Joshua
Egle Ian
Empfield James R.
Isaac Methvin
Ma Fupeng
AstraZeneca AB
Bianchi Kristin
Mitchell Kenneth F.
Saeed Kamal A
LandOfFree
Metabotropic glutamate-receptor-potentiating isoindolones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabotropic glutamate-receptor-potentiating isoindolones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabotropic glutamate-receptor-potentiating isoindolones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4239995